• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Cesano Alessandra was granted 27,000 shares, increasing direct ownership by 50% to 81,000 units (SEC Form 4)

    6/13/25 8:10:12 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBYI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cesano Alessandra

    (Last) (First) (Middle)
    C/O PUMA BIOTECHNOLOGY, INC.
    10880 WILSHIRE BLVD., SUITE 2150

    (Street)
    LOS ANGELES CA 90024

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PUMA BIOTECHNOLOGY, INC. [ PBYI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/11/2025 A 27,000 A $0(1) 81,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
    /s/ Gordon Esplin as attorney-in-fact for Alessandra Cesano 06/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PBYI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBYI

    DatePrice TargetRatingAnalyst
    9/28/2021$11.00Neutral → Buy
    Citigroup
    9/28/2021Neutral → Buy
    Citigroup
    8/6/2021$13.00 → $6.00Sector Perform
    RBC Capital
    8/6/2021$9.00 → $8.00Sell
    Goldman Sachs
    More analyst ratings

    $PBYI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, June 1, 2025

      6/4/25 5:33:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, April 1, 2025 a

      5/6/25 5:15:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Miller Michael Patrick was granted 27,000 shares, increasing direct ownership by 57% to 74,000 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      6/13/25 8:19:53 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Senderowicz Adrian was granted 27,000 shares, increasing direct ownership by 100% to 54,000 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      6/13/25 8:18:03 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Moyes Jay M was granted 27,000 shares, increasing direct ownership by 56% to 75,322 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      6/13/25 8:16:24 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Leadership Updates

    Live Leadership Updates

    See more
    • Puma Biotechnology to Join Russell 3000 Index

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor

      5/28/24 9:00:00 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

      Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

      11/17/22 4:15:00 PM ET
      $EPIX
      $PBYI
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

      Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper

      8/15/22 5:00:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Puma Biotech. upgraded by Citigroup with a new price target

      Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00

      9/28/21 7:42:41 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology upgraded by Citigroup

      Citigroup upgraded Puma Biotechnology from Neutral to Buy

      9/28/21 4:54:51 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Puma Biotechnology with a new price target

      RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously

      8/6/21 10:44:06 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    SEC Filings

    See more
    • Puma Biotechnology Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      6/13/25 4:07:53 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Puma Biotechnology Inc

      144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      6/13/25 4:04:58 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Inc filed SEC Form 8-K: Leadership Update

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/9/25 8:57:31 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Financials

    Live finance-specific insights

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of

      4/24/25 4:11:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat

      2/27/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care